1280: Bromide as Sole Drug Therapy for Treatment of Canine Epilepsy

Grant Status: Closed

Grant Amount: $40,196
Dawn Merton Boothe, DVM; Texas A&M University
September 23, 1996 - September 22, 1999

Sponsor(s):

Breed(s): -All Dogs
Research Program Area: Epilepsy Initiative
Donate to Support this Research Program Area

Project Summary

This study found that Phenobarbitol has fewer lasting side effects and is more effective than bromide in treating epileptic dogs and should remain the first-choice medication for most affected dogs. Researchers compared the two therapies to determine which should be the first drug that veterinarians turn to for epilepsy. The researchers enrolled 46 epileptic dogs (40 of them purebred) in the double-blinded study. They found that both drugs were associated with side effects including grogginess, vomiting, and increased hunger, thirst and urination. However, with the exception of vomiting, those effects diminished under both drugs. Twenty percent of the bromide dogs were still vomiting six months later. In addition, the Phenobarbital was more effective in eliminating seizures, as well as reducing the duration of seizures. The study also supports the currently recommended therapeutic ranges in both drugs.

Publication(s)

Boothe, D. M., Dewey, C., & Carpenter, D. M. (2012). Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs. Journal of the American Veterinary Medical Association, 240(9), 1073–1083. https://doi.org/10.2460/javma.240.9.1073

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617
(888)-682-9696

Tax ID# 13-3813813

  

© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.